GSK drug Nucala has expanded its FDA-approved uses to include maintenance treatment of chronic obstructive pulmonary disease that’s driven by eosinophils, a type of immune cell. The antibody drug will compete against the blockbuster Sanofi product Dupixent, which expanded its FDA approval to COPD last year.
Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA-approved indication for the blockbuster drug.
Your varicose or spider veins may indicate an underlying problem, so finding the right vein specialist is crucial. Discover the best vein clinics in Orlando.
European Medicines Agency approval of Dupixent in chronic obstructive pulmonary disease makes the drug the first biologic therapy approved for treating the prevalent respiratory condition. In COPD, Dupixent addresses what’s called type 2 inflammation.
Verona Pharma’s COPD drug Ohtuvayre is a single small molecule that blocks two targets to bring patients both bronchodilation and anti-inflammatory effects. Verona executives contend their inhalable drug has key advantages over the last novel COPD medication, the orally administered roflumilast.
The FDA turned down the British drugmaker's approval application for PT010, which won approval in Japan a few months ago and is marketed there as Breztri Aerosphere. GlaxoSmithKline won approval for a three-drug COPD inhaler, Trelegy Ellipta, in 2017.
Epharmix developed a unique, evidence-based tool to help both patients and clinicians.
Medical billing is a tedious administrative task, but outsourcing it may be the key to increased revenue. Explore the top medical billing outsourcing companies and the benefits of partnering with one.